Method for survival curve shifting in dogs
US5565495A · kind A · utility
0Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 1994 |
| Grant date | Oct 15, 1996 |
| Priority date | — |
| Expiry date | Sep 6, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Selegiline, or a pharmaceutically acceptable salt form of selegiline, is administered to mammals commencing at a point in time at which at least 50% of the mammal's life span is completed, with the administration continuing on a periodic but regular basis over the remaining life span of the mammal. The treatment, which shifts the survival curve, is especially useful for dogs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.